Peter J Elliott

Summary

Affiliation: Sirtris Pharmaceuticals
Country: USA

Publications

  1. ncbi Sirtuins: novel targets for metabolic disease
    Peter J Elliott
    Sirtris Pharmaceuticals Inc, 200 Technology Square, Cambridge, MA 02139, USA
    Curr Opin Investig Drugs 9:371-8. 2008
  2. doi Sirtuins--novel therapeutic targets to treat age-associated diseases
    Siva Lavu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    Nat Rev Drug Discov 7:841-53. 2008
  3. pmc Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
  4. pmc Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
  5. ncbi Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury
    Joseph Pye
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27516, USA
    Am J Physiol Heart Circ Physiol 284:H919-26. 2003
  6. ncbi Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Robert Z Orlowski
    Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7295, USA
    J Clin Oncol 20:4420-7. 2002
  7. pmc Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span
    Kevin J Pearson
    Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Cell Metab 8:157-68. 2008

Collaborators

  • Jill C Milne
  • Olivier Boss
  • Jean E Bemis
  • Robin J Johnson
  • Lei Jin
  • David A Sinclair
  • JERROLD MICHAEL OLEFSKY
  • Anna Csiszar
  • Z Ungvari
  • R Z Orlowski
  • Chi B Vu
  • Siva Lavu
  • Jesse J Smith
  • Philip D Lambert
  • Kevin J Pearson
  • Joseph Pye
  • Keith O Elliston
  • Brian P Frushour
  • RenĂ©e Deehan Kenney
  • David J Gagne
  • Heidi L Galonek
  • William Ladd
  • David P Carney
  • Giedre Razvadauskaite
  • Michael R Jirousek
  • Amy V Lynch
  • Kristine Israelian
  • Jeffrey Song
  • Andre Iffland
  • Placido Navas
  • Laura A Woollett
  • David Le Couteur
  • Stephen R Dunn
  • Kaitlyn N Lewis
  • Leonid Peshkin
  • Norman S Wolf
  • Evelyn Perez
  • Hamish A Jamieson
  • Robin K Minor
  • Rafael De Cabo
  • Joseph A Baur
  • Nazar Labinskyy
  • Kevin G Becker
  • Donald K Ingram
  • William R Swindell
  • Yongqing Zhang
  • Kumar Sharma
  • Nancy Pleshko
  • Nathan L Price
  • Davida Kamara
  • Yuji Ikeno
  • Thomas H Fischer
  • Arlene McCain
  • Julian Adams
  • Elizabeth Merricks
  • Albert S Baldwin
  • Christine Pien
  • Timothy C Nichols
  • Dwight A Bellinger
  • Farhad Ardeshirpour

Detail Information

Publications7

  1. ncbi Sirtuins: novel targets for metabolic disease
    Peter J Elliott
    Sirtris Pharmaceuticals Inc, 200 Technology Square, Cambridge, MA 02139, USA
    Curr Opin Investig Drugs 9:371-8. 2008
    ..As such, SRT-501 represents the first in a novel class of SIRT1 activators that has proven to be safe and well-tolerated in humans. Clinical trials in type 2 diabetic patients are currently underway...
  2. doi Sirtuins--novel therapeutic targets to treat age-associated diseases
    Siva Lavu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    Nat Rev Drug Discov 7:841-53. 2008
    ..Here, we discuss current knowledge and data that strengthens sirtuins as a druggable set of enzymes for the treatment of age-associated diseases, including activation of SIRT1 in type 2 diabetes...
  3. pmc Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
    ....
  4. pmc Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
    ..Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes...
  5. ncbi Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury
    Joseph Pye
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27516, USA
    Am J Physiol Heart Circ Physiol 284:H919-26. 2003
    ..These data show that myocardial reperfusion injury can be inhibited by using proteasome inhibitors, which likely function through the inhibition of NF-kappaB activation...
  6. ncbi Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Robert Z Orlowski
    Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7295, USA
    J Clin Oncol 20:4420-7. 2002
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies...
  7. pmc Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span
    Kevin J Pearson
    Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Cell Metab 8:157-68. 2008
    ..Our findings indicate that resveratrol treatment has a range of beneficial effects in mice but does not increase the longevity of ad libitum-fed animals when started midlife...